Skip to main content

Table 1 Summary of patient characteristics from the trastuzumab adjuvant trials

From: Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials

Characteristic (%) BCIRG006 NSABP/N9831 HERA FIN HER
Median age 49 50 49 51
Age<50 years 52 51 51 51
Diameter primary tumor (%)     
Tumor >= 20 mm 58 59.6 48.5 64.5
Estrogen receptor status (%)     
Positive 56 52.2 54.5 47
Negative 44 47.6 45.5 53
Progesterone receptor status (%)     
Positive 38 40.3 48.5 34
Negative 62 59.3 61.5 66
Node negative disease 29 5.7 32 16
Grade III tumor NA 69 60 65
Planed endocrine therapy 54 52 46 -
Taxane based chemotherapy 100 100 26 50
Quality trials by jadad scale 4 4 4 4